D
David N. Gilbert
Researcher at Providence Portland Medical Center
Publications - 105
Citations - 14572
David N. Gilbert is an academic researcher from Providence Portland Medical Center. The author has contributed to research in topics: Nephrotoxicity & Aminoglycoside. The author has an hindex of 38, co-authored 104 publications receiving 13324 citations. Previous affiliations of David N. Gilbert include Providence Regional Medical Center Everett & Oregon Health & Science University.
Papers
More filters
Journal ArticleDOI
Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
Helen W. Boucher,George H. Talbot,John S. Bradley,John S. Bradley,John E. Edwards,John E. Edwards,David N. Gilbert,Louis B. Rice,Louis B. Rice,Michael Scheld,Brad Spellberg,Brad Spellberg,John G. Bartlett +12 more
TL;DR: An update on potentially effective antibacterial drugs in the late-stage development pipeline is provided, in the hope of encouraging collaboration between industry, academia, the National Institutes of Health, the Food and Drug Administration, and the Centers for Disease Control and Prevention work productively together.
Journal ArticleDOI
The Epidemic of Antibiotic-Resistant Infections: A Call to Action for the Medical Community from the Infectious Diseases Society of America
Brad Spellberg,Robert Guidos,David N. Gilbert,John S. Bradley,John S. Bradley,Helen W. Boucher,W. Michael Scheld,John G. Bartlett,John E. Edwards +8 more
TL;DR: If the antimicrobial resistance crisis is to be addressed, a concerted, grassroots effort led by the medical community will be required and could mean a literal return to the preantibiotic era for many types of infections.
Book
The Sanford guide to antimicrobial therapy
David N. Gilbert,Robert C. Moellering,George M. Eliopoulos,Henry F. Chambers,Michael S. Saag +4 more
TL;DR: The sanford guide to antimicrobial therapy – trusted infectious diseaseRecommendations for antimicrobial usage and best practices for using antimicrobial agents in clinical practice are provided.
Journal ArticleDOI
Bad Bugs Need Drugs: An Update on the Development Pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America
George H. Talbot,John S. Bradley,John S. Bradley,John E. Edwards,David N. Gilbert,Michael Scheld,John G. Bartlett +6 more
TL;DR: The AATF has prepared this review to highlight pathogens that are frequently resistant to licensed antimicrobials and for which few, if any, potentially effective drugs are identifiable in the late-stage development pipeline.
Journal ArticleDOI
Combating antimicrobial resistance: policy recommendations to save lives.
Brad Spellberg,Martin J. Blaser,Robert Guidos,Helen W. Boucher,John S. Bradley,Barry I. Eisenstein,Dale N. Gerding,Ruth Lynfield,L B Reller,John H. Rex,Schwartz D,Edward Septimus,Fred C. Tenover,David N. Gilbert +13 more
TL;DR: This policy paper summarizes the Infectious Diseases Society of America’s (IDSA) recommendations about how best to address the synergistic crises of rising rates of antibiotic resistance and waning approvals of new antibiotics.